Safety and Care OF no Fasting prior to catheterisation laboratory procedures: a non-inferiority randomised control trial protocol (SCOFF Trial).

David Ferreira, Jack Hardy, Will Meere, Lloyd Butel-Simoes, Michael McGee, Nicholas Whitehead, Paul Healey, Tom Ford, Christopher Oldmeadow, John Attia, Bradley Wilsmore, Nicholas Collins, Andrew Boyle
{"title":"Safety and Care OF no Fasting prior to catheterisation laboratory procedures: a non-inferiority randomised control trial protocol (SCOFF Trial).","authors":"David Ferreira, Jack Hardy, Will Meere, Lloyd Butel-Simoes, Michael McGee, Nicholas Whitehead, Paul Healey, Tom Ford, Christopher Oldmeadow, John Attia, Bradley Wilsmore, Nicholas Collins, Andrew Boyle","doi":"10.1093/ehjopen/oead111","DOIUrl":null,"url":null,"abstract":"Abstract Introduction Cardiac catheterisation procedures are typically performed with local anaesthetic and proceduralist guided sedation. Various fasting regimens are routinely implemented prior to these procedures, noting an absence of prospective evidence, aiming to reduce aspiration risk. However, there are additional risks from fasting including patient discomfort, intravascular volume depletion, stimulus for neuro-cardiogenic syncope, glycaemic outcomes, and unnecessary fasting for delayed/cancelled procedures. Methods and Analysis This is an investigator-initiated, multicentre, randomised trial with a prospective, open-label, blinded endpoint (PROBE) assessment based in New South Wales, Australia. Patients will be randomised 1:1 to fasting (6 hours solid food, and 2 hours clear liquids) or to no fasting requirements. The primary outcome will be a composite of hypotension, hyperglycaemia, hypoglycaemia, and aspiration pneumonia. Secondary outcomes will include patient satisfaction, contrast induced nephropathy, new intensive care admission, new non-invasive or invasive ventilation requirement post procedure, and 30-day mortality and readmission. Ethics and Dissemination Ethics approval is confirmed via the Hunter New England Research Ethics Committee. The trial has been registered on the Australia New Zealand Clinical Trials Registry (ACTRN12622001455752). De-identified patient level data will be available to researchers who provide sound analysis proposals.","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European heart journal open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/ehjopen/oead111","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract Introduction Cardiac catheterisation procedures are typically performed with local anaesthetic and proceduralist guided sedation. Various fasting regimens are routinely implemented prior to these procedures, noting an absence of prospective evidence, aiming to reduce aspiration risk. However, there are additional risks from fasting including patient discomfort, intravascular volume depletion, stimulus for neuro-cardiogenic syncope, glycaemic outcomes, and unnecessary fasting for delayed/cancelled procedures. Methods and Analysis This is an investigator-initiated, multicentre, randomised trial with a prospective, open-label, blinded endpoint (PROBE) assessment based in New South Wales, Australia. Patients will be randomised 1:1 to fasting (6 hours solid food, and 2 hours clear liquids) or to no fasting requirements. The primary outcome will be a composite of hypotension, hyperglycaemia, hypoglycaemia, and aspiration pneumonia. Secondary outcomes will include patient satisfaction, contrast induced nephropathy, new intensive care admission, new non-invasive or invasive ventilation requirement post procedure, and 30-day mortality and readmission. Ethics and Dissemination Ethics approval is confirmed via the Hunter New England Research Ethics Committee. The trial has been registered on the Australia New Zealand Clinical Trials Registry (ACTRN12622001455752). De-identified patient level data will be available to researchers who provide sound analysis proposals.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
置管实验室操作前不禁食的安全性和护理:一项非劣效性随机对照试验方案(SCOFF试验)。
心导管手术通常在局部麻醉和程序性镇静的指导下进行。注意到缺乏前瞻性证据,在这些程序之前常规实施各种禁食方案,旨在降低误吸风险。然而,禁食还有其他风险,包括患者不适、血管内容量减少、神经心源性晕厥的刺激、血糖结局以及因延迟/取消手术而不必要的禁食。这是一项在澳大利亚新南威尔士州进行的前瞻性、开放标签、盲法终点(PROBE)评估的研究者发起、多中心、随机试验。患者将按1:1随机分配到禁食组(6小时固体食物和2小时透明液体)或不需要禁食组。主要结局将是低血压、高血糖、低血糖和吸入性肺炎的复合结局。次要结局包括患者满意度、造影剂肾病、新的重症监护入院、手术后新的无创或有创通气要求、30天死亡率和再入院。伦理和传播伦理批准由亨特新英格兰研究伦理委员会确认。该试验已在澳大利亚新西兰临床试验登记处注册(ACTRN12622001455752)。去识别患者水平的数据将提供给研究人员谁提供合理的分析建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
0
期刊最新文献
The incidence of atrial fibrillation detected by implantable loop recorders: a comparison between patients with and without embolic stroke of undetermined source. Intra-individual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate risk. New data allow to better understand the secrets of lipoprotein(a): is that for sure? Correction to: Correlates and consequences of atrial fibrillation in a prospective study of 25 000 participants in the China Kadoorie Biobank. Colchicine for cardiovascular and limb risk reduction in Medicare beneficiaries with peripheral artery disease: emulation of target trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1